Related Experiment Video
Updated: May 19, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3
Ching-Lung Cheung1, Kam-Shing Lau, Andrew Y Y Ho
1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, China.
Nature Genetics
|August 7, 2012
Summary
A genetic study identified a new risk locus on chromosome 17q24.3 associated with thyrotoxic periodic paralysis (TPP), a serious complication of thyrotoxicosis. This finding offers crucial insights into the genetic underpinnings of TPP.
Area of Science:
- Genetics
- Endocrinology
- Molecular Biology
Background:
- Thyrotoxic periodic paralysis (TPP) is a severe complication of thyrotoxicosis.
- Understanding the genetic basis of TPP is crucial for risk prediction and management.
Purpose of the Study:
- To identify genetic susceptibility loci for thyrotoxic periodic paralysis (TPP).
- To investigate the association between genetic variants and TPP risk in a Southern Chinese population.
Main Methods:
- Genome-wide association study (GWAS) and replication study.
- Analysis of 123 TPP cases and 1,170 healthy controls.
- Expression quantitative trait locus (eQTL) analysis near the KCNJ2 gene.
Main Results:
- A significant susceptibility locus for TPP was identified on chromosome 17q24.3 near KCNJ2 (rs312691, OR=3.3, P=1.8 × 10(-14)).
- The identified locus was specific to TPP, not Graves' disease alone.
- The rs312691 genotype showed predictive value for TPP risk in Graves' disease patients (AUC=0.73).
- SNPs near rs312691 potentially influence KCNJ2 gene expression.
Conclusions:
- A novel genetic locus associated with TPP has been discovered.
- This finding contributes to understanding the etiology of TPP.
- The identified genetic marker may aid in predicting TPP risk among individuals with Graves' disease.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...